ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.
Machaalani M, El Zarif T, Stockhammer P, Semaan K, Eid M, El Hajj Chehade R, Nawfal R, Yekeduz E, Nassar A, Lee G, Baca S, CHOUEIRI T, Grant M, Bellmunt J. ERBB2 mutations and association with molecular phenotype in urothelial carcinoma. Journal Of Clinical Oncology 2024, 42: 4590-4590. DOI: 10.1200/jco.2024.42.16_suppl.4590.Peer-Reviewed Original ResearchUpper tract UCTumor mutational burdenUrothelial carcinomaERBB2-targeted therapyMutant tumorsUC tumorsERBB2 amplificationMedian tumor mutation burdenHigh tumor mutational burdenWild type tumorsChi-square and Mann-Whitney U testsCombination therapy studiesMolecular phenotypesMann-Whitney U testTumor profile dataERBB2 mutationsBladder UCPolyPhen-2Mutational burdenType tumorsGenomic dataSolid tumorsClinical characteristicsCo-mutationsActivating mutationsComprehensive characterization of ERBB2 genomic alterations inlung cancer.
El Zarif T, Stockhammer P, Schillo J, Goldberg S, Politi K, Grant M. Comprehensive characterization of ERBB2 genomic alterations inlung cancer. Journal Of Clinical Oncology 2024, 42: 3148-3148. DOI: 10.1200/jco.2024.42.16_suppl.3148.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalShorter progression-free survivalTyrosine kinase domainSystemic therapyCo-mutationsClinical characteristics of non-small cell lung cancerCharacteristics of non-small cell lung cancerFirst-line platinum-based chemotherapyMedian tumor mutation burdenNon-small cell lung cancer tumorsFirst-line systemic therapyTP53 co-mutationsPlatinum-based chemotherapyTumor mutational burdenKaplan-Meier methodCell lung cancerLog-rank testOptimal treatment strategyHistory of smokingCopy number profilesTumor profile dataJuxtamembrane domainSquamous histologyTrastuzumab deruxtecan